Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Alectinib (Alecensaro) for Non-Small Cell Lung Cancer 
(Pending Submission as of December 8, 2017)

Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy) for Metastatic Melanoma
(Final Recommendation Issued as of November 30, 2017)

Midostaurin (Rydapt) for Acute Myeloid Leukemia 
(Open for Feedback on Recommendation until December 14, 2017)

Fulvestrant (Faslodex) for Locally Advanced or Metastatic Breast Cancer 
(Open for Feedback on Recommendation until December 14, 2017)

Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia 
(Open for Feedback on Recommendation until December 14, 2017)

Atezolizumab (Tecentriq) for Non-Small Cell Lung Cancer 
(Pending Submission as of November 17, 2017)

 

Find a Drug Review